Amniotic membrane extract or deferoxamine could be used interchangeably in angiogenesis within wound healing due to their high safety and availability.

No abstract

The present combination is a suitable mixture in control of experimental colitis and should be trialed in the clinical setting.

We aimed to review and meta‐analyze the inflammatory and oxidative factors following alpha lipoic acid (ALA) and its derivative “andrographolid‐lipoic acid‐1” (AL‐1) in ulcerative colitis (UC). ALA plays an important role in scavenging intracellular radicals and inflammatory elements. AL‐1 is found in herbal medicines with potent anti‐inflammatory properties. Data were collected from the Google Scholar, PubMed, Scopus, Evidence‐based medicine/clinical trials, and Cochrane library database until 2017, which finally resulted in 22 animal studies (70 rats and 162 mice). The beneficial effects of ALA or AL‐1 on the most important parameters of UC were reviewed; also, studies were considered separately in mice and rats. Administration of ALA and AL‐1 significantly reduced the tumor necrosis factor‐α level compared with the controls, while data were not noteworthy in the meta‐analysis (mean differences = −18.57 [95% CI = −42.65 to 5.51], P = 0.13). In spite of insignificant decrease in meta‐analysis outcomes (differences = 6.92 [95% CI = −39.33 to 53.16], P = 0.77), a significant reduction in myeloperoxidase activity was shown following ALA or AL‐1 treatment compared with the controls. Despite significant differences in each study, we had to exclude some studies to homogenize data for meta‐analyzing as they showed insignificant results. Interleukin 6, cyclooxygenase‐2, glutathione, malondialdehyde, superoxide dismutase, histopathological score, macroscopic and microscopic scores, disease activity index, body weight change, and colon length were also reviewed. Most studies have emphasized on significant positive effects of ALA and AL‐1. Comprehensive clinical trials are obligatory to determine the precious position of ALA or AL‐1 in the management of UC.

Without treatment, acute myeloid leukemia (AML) is almost always fatal. Spontaneous remission of AML is a rare phenomenon and usually with a short duration. The exact mechanisms are unknown. However, its association with infection and blood transfusions has been described. We report a 53-year-old male who presented with severe sepsis and who was diagnosed with AML (M4). He has experienced complete spontaneous remission with relatively long duration. To the best of our knowledge, it is the first case of spontaneous remission described in Iran.